Cover Image
市場調查報告書

泌尿道感染:開發中產品分析

Urinary Tract Infections - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 232831
出版日期 內容資訊 英文 139 Pages
訂單完成後即時交付
價格
Back to Top
泌尿道感染:開發中產品分析 Urinary Tract Infections - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 139 Pages
簡介

泌尿道感染(UTI),是由於細菌所引起的尿道感染疾病。女性的發病風險比男性要高。常見的症狀有強烈且持續性的尿意、排尿時的灼熱感、尿液混濁、骨盆痛(女性),直腸痛(男性)等。治療則使用抗生素。

本報告提供泌尿道感染的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

泌尿道感染概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • AstraZeneca PLC
  • ConjuGon, Inc.
  • Cubist Pharmaceuticals, Inc.
  • Da Volterra
  • DexTech Medical AB
  • FOB Synthesis, Inc.
  • GlycoVaxyn AG
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • Nabriva Therapeutics AG
  • NovaBay Pharmaceuticals, Inc.
  • Nymox Pharmaceutical Corporation
  • Osel Inc.
  • Paratek Pharmaceuticals, Inc.
  • Sequoia Sciences, Inc.
  • 鹽野義製藥
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.
  • The Medicines Company
  • Urinary Tract Infections

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (ceftaroline fosamil + avibactam sodium)
  • (ceftazidime + avibactam sodium)
  • (ceftolozane sulfate + tazobactam sodium)
  • (meropenem+ RPX-7009)
  • AA-139
  • auriclosene
  • C-1205
  • CatDex
  • cefepime
  • DAV-210
  • delafloxacin
  • Drugs to Inhibit COX-2 for Urinary Tract Infections
  • EBX-002
  • eravacycline
  • Escherichia coli vaccine
  • extraintestinal pathogenic escherichia coli vaccine
  • finafloxacin
  • FSI-1686
  • GP-4
  • klebsiella pneumoniae vaccine
  • LACTIN-V
  • Micselon
  • Nu-2
  • Nu-3
  • NXB-4221
  • omadacycline
  • plazomicin sulfate
  • Proteins for Infectious Deseases
  • relebactam
  • S-649266
  • Small Molecules to Inhibit 23S Ribosomal RNA for Infections
  • Vaccine for Urinary Tract Infection
  • ZTI-01 1

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6971IDB

Summary

Global Markets Direct's, 'Urinary Tract Infections - Pipeline Review, H2 2015', provides an overview of the Urinary Tract Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Urinary Tract Infections Overview
  • Therapeutics Development
    • Pipeline Products for Urinary Tract Infections - Overview
    • Pipeline Products for Urinary Tract Infections - Comparative Analysis
  • Urinary Tract Infections - Therapeutics under Development by Companies
  • Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes
  • Urinary Tract Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Urinary Tract Infections - Products under Development by Companies
  • Urinary Tract Infections - Products under Investigation by Universities/Institutes
  • Urinary Tract Infections - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • Adenium Biotech ApS
    • AstraZeneca Plc
    • ConjuGon, Inc.
    • Da Volterra
    • DexTech Medical AB
    • Enteris BioPharma, Inc.
    • GlaxoSmithKline Plc
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • MerLion Pharmaceuticals Pte Ltd
    • Nabriva Therapeutics AG
    • Nippon Shinyaku Co., Ltd.
    • NovaBay Pharmaceuticals, Inc.
    • Nymox Pharmaceutical Corporation
    • Paratek Pharmaceuticals, Inc.
    • Pivot Pharmaceuticals Inc
    • Sequoia Sciences, Inc.
    • Shionogi & Co., Ltd.
    • Syntiron LLC
    • The Medicines Company
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Urinary Tract Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ceftazidime + avibactam sodium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (meropenem+ RPX-7009) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • auriclosene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-7634 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-9074 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-9529 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-9563 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-1205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CatDex - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cefepime - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DAV-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit COX-2 for Urinary Tract Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EBX-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Escherichia coli vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fosfomycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GP-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-63871860 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Klebsiella pneumoniae vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Micselon - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nu-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXB-4221 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prulifloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • relebactam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-649266 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tobramycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • urinary tract infection vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Urinary Tract Infections - Recent Pipeline Updates
  • Urinary Tract Infections - Dormant Projects
  • Urinary Tract Infections - Discontinued Products
  • Urinary Tract Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 17, 2015: Paratek's Omadacycline, Demonstrates Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-Acquired Pneumonia and Urinary Tract Infections
      • Sep 02, 2015: Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
      • Aug 03, 2015: Paratek Pharmaceuticals to Present Data at ICAAC 2015
      • Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
      • Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
      • Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
      • Apr 27, 2015: Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
      • Apr 23, 2015: Actavis Launches AVYCAZ (Ceftazidime-Avibactam) Anti-Infective In U.S.
      • Apr 09, 2015: Achaogen to Present at 14th Annual Needham Healthcare Conference
      • Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Urinary Tract Infections, H2 2015
  • Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Urinary Tract Infections - Pipeline by Achaogen Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H2 2015
  • Urinary Tract Infections - Pipeline by AstraZeneca Plc, H2 2015
  • Urinary Tract Infections - Pipeline by ConjuGon, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Da Volterra, H2 2015
  • Urinary Tract Infections - Pipeline by DexTech Medical AB, H2 2015
  • Urinary Tract Infections - Pipeline by Enteris BioPharma, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
  • Urinary Tract Infections - Pipeline by Merck & Co., Inc., H2 2015
  • Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2015
  • Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H2 2015
  • Urinary Tract Infections - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
  • Urinary Tract Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H2 2015
  • Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Pivot Pharmaceuticals Inc, H2 2015
  • Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Shionogi & Co., Ltd., H2 2015
  • Urinary Tract Infections - Pipeline by Syntiron LLC, H2 2015
  • Urinary Tract Infections - Pipeline by The Medicines Company, H2 2015
  • Urinary Tract Infections - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Urinary Tract Infections - Dormant Projects, H2 2015
  • Urinary Tract Infections - Dormant Projects (Contd..1), H2 2015
  • Urinary Tract Infections - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Urinary Tract Infections, H2 2015
  • Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top